Sofía Lucila Rodríguez-Rivera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sofía Lucila Rodríguez-Rivera has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Martín Arturo Silva-Ramírez
UPIITA Instituto Politcnico Nacional,Ciudad de Mxico,Mxico
2 shared publications - Paula Ramírez-Palacios
Center for Evaluation and Surveys Research National Institute of Public Health Cuernavaca Mexico
2 shared publications - Ricardo Iván Montaño-González
Universidad Tecnológica de México, Mexico
2 shared publications Cinthya Carolina Avalos Román
General Hospital No. 33, Mexican Institute of Social Security, Monterrey, Mexico
1 shared publicationFabiola Marycruz De la Fuente-Silva
Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México City, México
1 shared publication- Fabiola Marycruz De la Fuente-Silva1 shared publication
Latest Publications
- Open Access
- 6 March 2026
- Published by Scholar Publishing in British Journal of Healthcare and Medical Research
- Vol. 13 (02) , 81-95
Identifying Prognostic Factors for Drug-Resistant Epilepsy in Children with Cerebral Palsy
Background and purpose: Drug-resistant epilepsy is a common and disabling complication in children with cerebral palsy (CP). This study aimed to analyze the relationship between neurological, functional, and perinatal factors and the development of drug-resistant epilepsy in pediatric patients with CP to determine prognostic factors and improve medical management. Methods: We compared three groups of patients with cerebral palsy: those with drug-resistant epilepsy, those with drug-sensitive epilepsy, and those without epilepsy. Clinical variables, perinatal history, characteristics of seizure onset, neuroimaging findings, functional scales (GMFCS, MACS), and comorbidities were collected. Associations were evaluated using appropriate statistical tests, including Fisher's exact test, multiple logistic regression, and inferential statistics in Epi Info™ version 7.2. Results: We studied 80 patients. Drug-resistant epilepsy was present in 49 (61%) of the participants. It was significantly associated with quadriplegic motor involvement (p=0.04), early seizure onset (p=0.03), and corticosubcortical atrophy on neuroimaging (20%, n=16). The need for gastrostomy (p=0.03) and the use of dual therapy (p=0.06) or polytherapy (p=0.008) were also strongly related to drug resistance. Conclusions: Drug-resistant epilepsy in children with CP is strongly linked to markers of severe neurological compromise and early epileptic manifestations, rather than to isolated perinatal complications. Early identification of high-risk profiles may guide timely diagnostic and therapeutic strategies to improve clinical outcomes.
- 6 March 2026
- Published by Scholar Publishing in British Journal of Healthcare and Medical Research
- Vol. 13 (02) , 81-95
Open AccessIdentifying Prognostic Factors for Drug-Resistant Epilepsy in Children with Cerebral Palsy
Background and purpose: Drug-resistant epilepsy is a common and disabling complication in children with cerebral palsy (CP). This study aimed to analyze the relationship between neurological, functional, and perinatal factors and the development of drug-resistant epilepsy in pediatric patients with CP to determine prognostic factors and improve medical management. Methods: We compared three groups of patients with cerebral palsy: those with drug-resistant epilepsy, those with drug-sensitive epilepsy, and those without epilepsy. Clinical variables, perinatal history, characteristics of seizure onset, neuroimaging findings, functional scales (GMFCS, MACS), and comorbidities were collected. Associations were evaluated using appropriate statistical tests, including Fisher's exact test, multiple logistic regression, and inferential statistics in Epi Info™ version 7.2. Results: We studied 80 patients. Drug-resistant epilepsy was present in 49 (61%) of the participants. It was significantly associated with quadriplegic motor involvement (p=0.04), early seizure onset (p=0.03), and corticosubcortical atrophy on neuroimaging (20%, n=16). The need for gastrostomy (p=0.03) and the use of dual therapy (p=0.06) or polytherapy (p=0.008) were also strongly related to drug resistance. Conclusions: Drug-resistant epilepsy in children with CP is strongly linked to markers of severe neurological compromise and early epileptic manifestations, rather than to isolated perinatal complications. Early identification of high-risk profiles may guide timely diagnostic and therapeutic strategies to improve clinical outcomes.
- Open Access
- 18 September 2023
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
- Vol. 29 (2)
PEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC
Introduction: Guillain-Barré Syndrome is the most common cause of acute flaccid paralysis in childhood. It is a post infectious disease immune-mediated with a rapidly progressive course, usually without relapse. The main features are progressive weakness of more than one limb, areflexia or hyporeflexia, which gets progressively worst over days-to-weeks, to potentially life-threatening severity requiring mechanical ventilation. Objective: We aimed to describe the clinical features of pediatric Guillain-Barré Syndrome in México before and during SARS-CoV-2 pandemic. Methods: We performed an ambispective, observational, cross-sectional study in a Mexican reference hospital from January 2013 to December 2021. Data were obtained through records: demographic, clinical, laboratories, neurophysiological variants and treatment. Results: Here we show that of the 96 patients, 55 were males with mean age of 9 years, 72% had history of infection; progressive weakness was present in 97%, areflexia/hyporeflexia 97%, progression of symptoms 99%, mean cells of 9/mm3 and mean proteins 88 mg/dL. Admission to Pediatric Intensive Care Unit was 20%. Acute Motor Axonal Neuropathy was the most frequent subtype. Nineteen patients required mechanical ventilation. Immunoglobulin was administered in 88%. Most frequent Disability Score at discharge was bedridden/wheelchair-bound. During 2020-2021 we found two SARS-CoV-2 cases and one associated with BNT162b2 vaccine. Conclusions: Our results demonstrate that clinical features of pediatric Guillain-Barré Syndrome are similar before and during SARS-CoV-2 pandemic, nevertheless the number of cases associated with SARS-CoV-2 infection did not find increase.
- 18 September 2023
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
- Vol. 29 (2)
Open AccessPEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC
Introduction: Guillain-Barré Syndrome is the most common cause of acute flaccid paralysis in childhood. It is a post infectious disease immune-mediated with a rapidly progressive course, usually without relapse. The main features are progressive weakness of more than one limb, areflexia or hyporeflexia, which gets progressively worst over days-to-weeks, to potentially life-threatening severity requiring mechanical ventilation. Objective: We aimed to describe the clinical features of pediatric Guillain-Barré Syndrome in México before and during SARS-CoV-2 pandemic. Methods: We performed an ambispective, observational, cross-sectional study in a Mexican reference hospital from January 2013 to December 2021. Data were obtained through records: demographic, clinical, laboratories, neurophysiological variants and treatment. Results: Here we show that of the 96 patients, 55 were males with mean age of 9 years, 72% had history of infection; progressive weakness was present in 97%, areflexia/hyporeflexia 97%, progression of symptoms 99%, mean cells of 9/mm3 and mean proteins 88 mg/dL. Admission to Pediatric Intensive Care Unit was 20%. Acute Motor Axonal Neuropathy was the most frequent subtype. Nineteen patients required mechanical ventilation. Immunoglobulin was administered in 88%. Most frequent Disability Score at discharge was bedridden/wheelchair-bound. During 2020-2021 we found two SARS-CoV-2 cases and one associated with BNT162b2 vaccine. Conclusions: Our results demonstrate that clinical features of pediatric Guillain-Barré Syndrome are similar before and during SARS-CoV-2 pandemic, nevertheless the number of cases associated with SARS-CoV-2 infection did not find increase.
- Open Access
- 18 September 2023
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
PEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC
Introduction: Guillain-Barré Syndrome is the most common cause of acute flaccid paralysis in childhood. It is a post infectious disease immune-mediated with a rapidly progressive course, usually without relapse. The main features are progressive weakness of more than one limb, areflexia or hyporeflexia, which gets progressively worst over days-to-weeks, to potentially life-threatening severity requiring mechanical ventilation. Objective: We aimed to describe the clinical features of pediatric Guillain-Barré Syndrome in México before and during SARS-CoV-2 pandemic. Methods: We performed an ambispective, observational, cross-sectional study in a Mexican reference hospital from January 2013 to December 2021. Data were obtained through records: demographic, clinical, laboratories, neurophysiological variants and treatment. Results: Here we show that of the 96 patients, 55 were males with mean age of 9 years, 72% had history of infection; progressive weakness was present in 97%, areflexia/hyporeflexia 97%, progression of symptoms 99%, mean cells of 9/mm3 and mean proteins 88 mg/dL. Admission to Pediatric Intensive Care Unit was 20%. Acute Motor Axonal Neuropathy was the most frequent subtype. Nineteen patients required mechanical ventilation. Immunoglobulin was administered in 88%. Most frequent Disability Score at discharge was bedridden/wheelchair-bound. During 2020-2021 we found two SARS-CoV-2 cases and one associated with BNT162b2 vaccine. Conclusions: Our results demonstrate that clinical features of pediatric Guillain-Barré Syndrome are similar before and during SARS-CoV-2 pandemic, nevertheless the number of cases associated with SARS-CoV-2 infection did not find increase.
- 18 September 2023
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
Open AccessPEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC
Introduction: Guillain-Barré Syndrome is the most common cause of acute flaccid paralysis in childhood. It is a post infectious disease immune-mediated with a rapidly progressive course, usually without relapse. The main features are progressive weakness of more than one limb, areflexia or hyporeflexia, which gets progressively worst over days-to-weeks, to potentially life-threatening severity requiring mechanical ventilation. Objective: We aimed to describe the clinical features of pediatric Guillain-Barré Syndrome in México before and during SARS-CoV-2 pandemic. Methods: We performed an ambispective, observational, cross-sectional study in a Mexican reference hospital from January 2013 to December 2021. Data were obtained through records: demographic, clinical, laboratories, neurophysiological variants and treatment. Results: Here we show that of the 96 patients, 55 were males with mean age of 9 years, 72% had history of infection; progressive weakness was present in 97%, areflexia/hyporeflexia 97%, progression of symptoms 99%, mean cells of 9/mm3 and mean proteins 88 mg/dL. Admission to Pediatric Intensive Care Unit was 20%. Acute Motor Axonal Neuropathy was the most frequent subtype. Nineteen patients required mechanical ventilation. Immunoglobulin was administered in 88%. Most frequent Disability Score at discharge was bedridden/wheelchair-bound. During 2020-2021 we found two SARS-CoV-2 cases and one associated with BNT162b2 vaccine. Conclusions: Our results demonstrate that clinical features of pediatric Guillain-Barré Syndrome are similar before and during SARS-CoV-2 pandemic, nevertheless the number of cases associated with SARS-CoV-2 infection did not find increase.